CLABSI | Search

临床试验

计划入组 120 人 · 首次发布于 2026 年 2 月 24 日

招募中

NCT05721677

CLABSI Prevention With Tissue Adhesive

计划入组 600 人 · 首次发布于 2023 年 2 月 10 日

已完成

NCT02575079

Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

计划入组 119 人 · 首次发布于 2015 年 10 月 14 日

药物

查看全部 57 →

Calbi

Biotech

Experimental

Bacillus clausii

相关疾病：Abdominal Pain, Abnormal Intestinal Absorption，另有 3 项

Filgrastim biosimilar (Claris Lifesciences)

机构

查看全部 95 →

Clavis Pharma

Norway

Claris Biotherapeutics, Inc.

United States

CLARIS LIFESCIENCES INC

United States

资讯

查看全部 643 →

去年

Chlorhexidine-Impregnated Central Venous Catheters Reduce ICU Bloodstream Infections by 70.5% in Multinational Study

去年

Citius Pharma Gains FDA Guidance on Mino-Lok Phase 3 Program for CLABSI

去年

临床试验

Impact of Disinfectant Caps on Nosocomial CLABSI

CLABSI Prevention With Tissue Adhesive

Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT

药物

Calbi

Bacillus clausii

Filgrastim biosimilar (Claris Lifesciences)

机构

Clavis Pharma

Claris Biotherapeutics, Inc.

CLARIS LIFESCIENCES INC

资讯

Chlorhexidine-Impregnated Central Venous Catheters Reduce ICU Bloodstream Infections by 70.5% in Multinational Study

Citius Pharma Gains FDA Guidance on Mino-Lok Phase 3 Program for CLABSI

Citius Pharma Gains Clarity on Mino-Lok's Regulatory Path After FDA Meeting